FdaApplication
BLA 103928
Identifiers
- fda_app_no: BLA103928
Properties
| Property | Value |
|---|---|
| applicant_name | Palatin Technologies, Inc. |
| application_type | BLA |
| approval_date | 2004-07-02 |
Revenue by product
NEUTROSPEC
| Period | Revenue |
|---|---|
| Q2 2026 | $0.3M† |
| Q1 2026 | $3.9M† |
| Q3 2025 | $8.8M† |
| Q2 2025 | $0.0M† |
| Q1 2025 | $0.0M† |
| Q3 2024 | $0.0M† |
| Q2 2024 | $0.3M† |
| Q1 2024 | $0.0M† |
| Q4 2023 | $2.0M† |
| Q3 2023 | $2.1M† |
| Q2 2023 | $1.8M† |
| Q1 2023 | $1.2M† |
| Q4 2022 | $1.0M† |
| Q3 2022 | $0.9M† |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one. A figure marked † is the company's one reported revenue line rather than a product breakdown.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| NEUTROSPEC | — | 0.25MG | Injection |
1 product